TKNO
Alpha Teknova, Inc.
Key Financials
Net Income
$-17259000
↑ 35.5%
Gross Profit
$13.4M
↑ 85.9%
Operating Income
$-16976000
↑ 35.1%
Revenue
$40.5M
↑ 7.4%
Total Liabilities
$34.8M
↓ 4.3%
Total Assets
$103.6M
↓ 12.8%
Shareholders' Equity
$68.8M
↓ 16.5%
EPS (Diluted)
$-0.32
↑ 43.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 10-K | 3/2/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| 10-Q | 11/7/2025 | View on SEC |
| 8-K | 11/6/2025 | View on SEC |
| 10-Q | 8/8/2025 | View on SEC |
| 8-K | 8/7/2025 | View on SEC |
| EFFECT | 7/16/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TKNO |
| Company Name | Alpha Teknova, Inc. |
| CIK | 1850902 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 8316371100 |